Agenus Inc. (AGEN) AI Stock Analysis

Headquartered in Lexington, Massachusetts, Agenus Inc. is a clinical-stage immuno-oncology company focused on discovering and developing cancer therapies. The company utilizes its proprietary Retrocyte Display platform along with other display technologies to identify human and humanized monoclonal antibodies. Its pipeline includes vaccine programs like the Prophage vaccine candidate and QS-21 Stimulon adjuvant, as well as antibody therapies such as Balstilimab, AGEN1181, AGEN2373, and AGEN1423. Agenus collaborates with industry partners including Incyte Corporation, Merck Sharp & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. to advance treatments across various cancer indications.

From FY2020 to FY2025, Agenus achieved a 5-year revenue CAGR of 5.3%. Annual revenue moved from $295.7M in FY2021 to $98.0M in FY2022, $156.3M in FY2023, $103.5M in FY2024, and reached $114.2M in FY2025, representing 10.4% year-over-year growth. Operating margin was -18.0% in FY2025, recovering from -116.4% in FY2024. Net income turned slightly positive at $115,000 in FY2025 compared to -$227.2M in FY2024, though EPS was -$2.51. For the trailing twelve months ended June 30, 2026, revenue stood at $132.7M with a profit margin of 69.3%, while quarterly revenue growth was 34.4% year-over-year.

As of June 30, 2026, Agenus held $18.7M in cash and short-term investments against total debt of $40.7M, resulting in net debt of $22.0M. The company has negative shareholders' equity of -$199.1M, total assets of $172.7M, and a current ratio of 0.34. In FY2025, operating cash flow was -$158.3M and free cash flow was -$158.9M. Cash uses in FY2025 included capital expenditures of $576,000 and share buybacks of $87,000, while the share count expanded by 235.1% over 5 years.

Agenus trades at an enterprise value of $401.3M and a market capitalization of $272.8M. Its trailing P/E is 2.6x and forward P/E is 3.7x, both well below the median of its US-listed Healthcare peers at 24.6x and 17.3x, respectively. The company's price-to-sales ratio is 2.1x compared to the peer median of 4.1x, and its EV-to-EBITDA is 2.2x versus the peer median of 12.0x. Over the past year, the stock gained 51.4%, outperforming the S&P 500 return of 16.8%, though its 5-year return of -94.2% trails the index return of 83.0%.

Wall Street coverage consists of 3 Strong Buy ratings and no Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $26.33, indicating an upside of 336.0% from the last close of $6.04 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate EPS of $0.50 and revenue of $125.2M. The company beat EPS estimates in 1 of the last 4 quarters. The next earnings date is November 9, 2026.

This page is an AI-written research summary of Agenus Inc. (AGEN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AGEN income statement, AGEN balance sheet, AGEN key metrics, AGEN analyst forecast, AGEN chart. See the AGEN stock overview for the latest quote and news.